Released: Friday 16th April 2021

Breakthrough Respiratory Health Platform Aims to Save
Thousands of Lives Annually

UK based Altair Medical today announced it has secured £2.25m ($3.1m) of Pre-Series A funding to
further develop its respiratory sensor and real-time monitoring platform. The service uses AI to
detect and alert to adverse events from a range of breathing problems, with the hope of preventing
a large number of early deaths.

We normally take our breathing for granted but our lungs are vital organs that are vulnerable to infection,
disease and reduced function. Collectively, these respiratory conditions are a leading cause of disability and
death globally.

Altair Medical, a UK based Digital Health company, is developing a breakthrough wearable sensor that aims to
radically improve patient outcomesin numerous clinical situations. It is one of the smallest available biosensors
and transmits data to a cloud platform using a data hub or smartphone. Alerting the patient, their household
members, doctor, nurse or emergency services where life-threatening changes occur, Altair’s technology will
be able to accurately monitor very large numbers of patients in any location simultaneously.

Altair’s CEO, Dr Bruce Henderson, explains.

“From my work as a forensic medical examiner I witnessed a large number of preventable deaths from
patients with respiratory conditions. This inspired me to build up a team of specialists to develop the
technology, which is now undergoing clinical trials in a range of respiratory conditions.

We see huge potential for our device across a wide range of patients. We are delighted to have secured
the backing of a syndicate of investors, which allows us to further prove the device and launch it in the UK,
US and other countries in the near future.”

Altair’s original funding target has been significantly oversubscribed, a sign of confidence by its backers in the
potential of the technology. Confidence which was further boosted by Altair being awarded Breakthrough
Medical Device designation from the US Food & Drug Administration (FDA).

Altair’s investor syndicate was led by Alba Equity and includes Equity Gap, Intuitive Investment Group plc (IIG),
London and Scottish Investment Partners and Scottish Enterprise.

John Duncan of Alba Equity commented:

“We are delighted to support Altair with this investment, alongside a strong syndicate of investor groups.
Altair are developing technology which is already demonstrating its potential to help save lives in ongoing
clinical trials and this investment will allow the company to bring this to the market, offering significant
benefits to a large number of patients.”

Dr Stewart White of IIG, who will be taking a seat on the Board, comments.

“IIG is a fund focussing on high potential life science business, so Altair Medical fits perfectly with our
investment criteria.

The Altair technology, which is undergoing patent approval in the US and UK, has various unique properties
that make it attractive for use in respiratory health applications and we’re excited to fund its development.”

Recognised as an early stage company with high growth potential, Altair Medical has been supported by
Scottish Enterprise’s High Growth ventures team. With the device’s global market opportunity estimated at
$8 billion, the company is confident that with investment and support, its unique technology will secure a
strong market share and improve the medical outcomes of thousands of people globally. Funding will be used
to validate the performance characteristics of the technology prior to applying for Class 2 Medical Device
regulatory clearance.

Altair Medical was advised throughout by Ascendant Corporate Finance and DCS Legal. The investor syndicate
was advised by Wright, Johnston & Mackenzie.

ABOUT ALTAIR MEDICAL

Based in the UK, Altair Medical was established in early 2018 by Dr Bruce Henderson, a specialist physician
and founder of COMS, a successful healthcare services company, and by Jonathan Guthrie, a chartered
accountant and entrepreneur who founded technology and outsource CRM businesses Paywizard and MGt.
With a mission to reduce the global burden from respiratory illness, Altair Medical’s technology has been
developed by an international team of specialists with experience of hardware and software development,
data analysis and artificial intelligence. Performance characteristics are not yet fully established and the
technology will not be made available commercially until it demonstrates conformity with applicable
regulatory requirements.

For more information, see www.altairmedical.com

SOCIAL MEDIA SHARING
If linking to this article via social media, we encourage the use of the following hashtags
#RespiratoryCare
#MedicalSensor
#Covid19